DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells

Experimental and Molecular Pathology

Volumn 96, Issue 1, 2014, Pages 108-117

  Bhopale, Mahendra K ^a   Hilliard, Brendan ^a   Constantinescu, Cris S ^b   Fujioka, Toshiki ^c   Ventura, Elvira ^d   Phillips, S Michael ^d   Rostami, Abdolmohamad ^e  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cytokine expression; DAB389IL 2; EAE; Oligodendrocyte; T cell cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2; MESSENGER RNA;

ANIMAL; ARTICLE; ASTROCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOKINE EXPRESSION; CYTOTOXIC T LYMPHOCYTE; DAB(389)IL-2; DRUG EFFECT; EAE; ENZYME IMMUNOASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENETICS; GLIA; HUMAN; IMMUNOLOGY; INFLAMMATION; LEWIS RAT; LYMPHOCYTE ACTIVATION; METABOLISM; OLIGODENDROGLIA; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CYTOKINE EXPRESSION; DAB(389)IL-2; EAE; OLIGODENDROCYTE; T CELL CYTOTOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; DIPHTHERIA TOXIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; NEUROGLIA; RATS; RATS, INBRED LEW; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84893823633     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.07.004     Document Type: Article

References (62)

1. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. The Journal of Experimental Medicine 2003, 197:725-733.
2. Almeras L., Meresse B., Seze J., De Lefranc D., Dubucquoi S., Fajardy I., Vermersch P., Prin L. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. European Cytokine Network 2002, 13:200-206.
3. Bacha P., Williams D.P., Waters C., Williams J.M., Murphy J.R., Strom T.B. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. The Journal of Experimental Medicine 1988, 167:612-622.
4. Bacha P.A., Forte S.E., McCarthy D.M., Estis L., Yamada G., Nichols J.C. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. International Journal of Cancer 1991, 49:96-101.
5. Bacha P., Forte S.E., Perper S.J., Trentham D.E., Nichols J.C. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis. European Journal of Immunology 1992, 22:1673-1679.
6. Balcer L.J., McIntosh K.R., Nichols J.C., Drachman D.B. Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies. Journal of Neuroimmunology 1991, 31:115-122.
7. Bauer J., Sminia T., Wouterlood F.G., Dijkstra C.D. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. Journal of Neuroscience Research 1994, 38:365-375.
8. Bauer J., Huitinga I., Zhao W., Lassmann H., Hickey W.F., Dijkstra C.D. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 1995, 15:437-446.
9. Bullard D.C., Hu X., Adams J.E., Schoeb T.R., Barnum S.R. p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. American Journal of Pathology 2007, 170:2001-2008.
10. Calida D.M., Kremlev S.G., Fujioka T., Hilliard B., Ventura E., Constantinescu C.S., Lavi E., Rostami A. Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12. Journal of Neuroimmunology 2000, 107:1-7.
11. Deibler G.E., Martenson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Preparative Biochemistry 1972, 2(2):139-165.
12. Duszczyszyn D.A., Beck J.D., Antel J., Bar-Or A., Lapierre Y., Gadag V., Haegert D.G. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clinical and Experimental Immunology 2006, 143:305-313.
13. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., Zhang G.X., Dittel B.N., Rostami A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nature Immunology 2011, 12:568-575.
14. Elliott J.I., Douek D.C., Altmann D.M. Mice lacking alpha beta+T cells are resistant to the induction of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 1996, 70:139-144.
15. Gao Y.L., Rajan A.J., Raine C.S., Brosnan C.F. gammadelta T cells express activation markers in the central nervous system of mice with chronic-relapsing experimental autoimmune encephalomyelitis. Journal of Autoimmunity 2001, 17:261-271.
16. Golovina T.N., Vonderheide R.H. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer Journal 2010, 16(4):342-347. (Review).
17. Goverman J., Perchellet A., Huseby E.S. The role of CD8(+) T cells in multiple sclerosis and its animal models. Current Drug Targets. Inflammation and Allergy 2005, 4:239-245. (Review).
18. Graeber M.B., Streit W.J., Kiefer R., Schoen S.W., Kreutzberg G.W. New expression of myelomonocytic antigens by microglia and perivascular cells following lethal motor neuron injury. Journal of Neuroimmunology 1990, 27:121-132.
19. Haegele K.F., Stueckle C.A., Malin J.P., Sindern E. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. Journal of Neuroimmunology 2007, 183:168-174.
20. Hayashi R.J., Kanagawa O. Requirement of high-affinity IL-2-IL-2R interaction for T cell anergy induction. International Immunology 2006, 18(5):645-651. (Epub 2006 Mar 30).
21. Hobeika A.C., Morse M.A., Osada T., Peplinski S., Lyerly H.K., Clay T.M. Depletion of human regulatory T cells. Methods in Molecular Biology 2011, 707:219-231.
22. Hochman P.S., Majeau G.R., Mackay F., Browning J.L. Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands. Journal of Inflammation 1995-1996, 46(4):220-234.
23. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scandinavian Journal of Immunology 2011, 74:1-13.
24. Juedes A.E., Ruddle N.H. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. Journal of Immunology 2001, 166:5168-5175.
25. Kadin M.E., Vonderheid E.C. Targeted therapies: Denileukin diftitox-a step towards a 'magic bullet' for CTCL. Nature Reviews. Clinical Oncology 2010, 7:430-432.
26. Kawai K., Zweiman B. Cytotoxic effect of myelin basic protein-reactive T cells on cultured oligodendrocytes. Journal of Neuroimmunology 1988, 19:159-165.
27. Kawai K., Zweiman B. Characteristics of in vitro cytotoxic effects of myelin basic protein-reactive T cell lines on syngeneic oligodendrocytes. Journal of Neuroimmunology 1990, 26:57-67.
28. Kawakami K., Nakajima O., Morishita R., Nagai R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. The Scientific World Journal 2006, 6:781-790. (Review).
29. Klyushnenkova E.N., Vanguri P. Ia expression and antigen presentation by glia: strain and cell type-specific differences among rat astrocytes and microglia. Journal of Neuroimmunology 1997, 79:190-201.
30. Lansigan F., Stearns D.M., Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management and Research 2010, 2:53-59.
31. Lavasani S., Dzhambazov B., Andersson M. Monoclonal antibody against T-cell receptor alphabeta induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scandinavian Journal of Immunology 2007, 65:39-47.
32. Litzinger M.T., Fernando R., Curiel T.J., Grosenbach D.W., Schlom J., Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-3201.
33. Lyman W.D., Roth G.A., Chiu F.C., Brosnan C.F., Bornstein M.B., Raine C.S. Antigen-specific T cells can mediate demyelination in organotypic central nervous system cultures. Cellular Immunology 1986, 102:217-226.
34. Matsushita N., Pilon-Thomas S.A., Martin L.M., Riker A.I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. Journal of Immunological Methods 2008, 333:167-179.
35. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nature Medicine 2005, 11:335-339.
36. Miller S.D., McMahon E.J., Schreiner B., Bailey S.L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Annals of the New York Academy of Sciences 2007, 1103:179-191.
37. Murzenok P.P., Matusevicius D., Freedman M.S. gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clinical Immunology 2002, 103:309-316.
38. Natarajan N., Telang S., Miller D., Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011, 71:1233-1250.
39. Nguyen K.B., McCombe P.A., Pender M.P. Macrophage apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. Journal of Autoimmunity 1994, 7:145-152.
40. Pacheco-Silva A., Bastos M.G., Muggia R.A., Pankewycz O., Nichols J., Murphy J.R., Strom T.B., Rubin-Kelley V.E. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. European Journal of Immunology 1992, 22:697-702.
41. Papadopoulos D., Pham-Dinh D., Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Experimental Neurology 2006, 197:373-385.
42. Pastor S., Vaccaro C.G., Minguela A., Ober R.J., Ward E.S. Analyses of TCR clustering at the T cell-antigen-presenting cell interface and its impact on the activation of naive CD4+ T cells. International Immunology 2006, 18:1615-1625.
43. Petro T.M. Regulatory role of resveratrol on Th17 in autoimmune disease. International Immunopharmacology 2011, 11(3):310-318. (Review).
44. Phillips S.M., Bhopale M.K., Constantinescu C.S., Ciric B., Hilliard B., Ventura E., Lavi E., Rostami A. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. Journal of the Neurological Sciences 2007, 263:59-69.
45. Phillips S.M., Bhopale M.K., Hilliard B., Zekavat S.A., Ali M.A., Rostami A. Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2. Cellular Immunology 2010, 261:144-152.
46. Ponomarev E.D., Novikova M., Yassai M., Szczepanik M., Gorski J., Dittel B.N. Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis. Journal of Immunology 2004, 173:1587-1595.
47. Ponomarev E.D., Shriver L.P., Maresz K., Dittel B.N. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. Journal of Neuroscience Research 2005, 81(3):374-389.
48. Potala S., Verma R.S. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - construction and characterization. Journal of Biotechnology 2010, 148:147-155.
49. Ramadan M.A., Gabr N.S., Bacha P., Günzler V., Phillips S.M. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy. Cellular Immunology 1995, 166:217-226.
50. Ratts R.B., Karandikar N.J., Hussain R.Z., Choy J., Northrop S.C., Lovett-Racke A.E., Racke M.K. Phenotypic characterization of autoreactive T cells in multiple sclerosis. Journal of Neuroimmunology 2006, 178:100-110.
51. Remington L.T., Babcock A.A., Zehntner S.P., Owens T. Microglial recruitment, activation, and proliferation in response to primary demyelination. American Journal of Pathology 2007, 170(5):1713-1724.
52. Rinner W.A., Bauer J., Schmidts M., Lassmann H., Hickey W.F. Resident microglia and hematogenous macrophages as phagocytes in adoptively transferred experimental autoimmune encephalomyelitis: an investigation using rat radiation bone marrow chimeras. Glia 1995, 14:257-266.
53. Rostami A., Gregorian S.K., Brown M.J., Pleasure D.E. Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. Journal of Neuroimmunology 1990, 2-3:145-151.
54. Röyttä M., Lyman W.D., Roth G.A., Bornstein M.B., Raine C.S. Preliminary analysis of cell and serum-induced demyelination in vitro using a syngeneic system. Acta Neurologica Scandinavica 1985, 71:226-236.
55. Sadler R.H., Sommer M.A., Forno L.S., Smith M.E. Induction of anti-myelin antibodies in EAE and their possible role in demyelination. Journal of Neuroscience Research 1991, 30(4):616-624.
56. Siegling A., Lehmann M., Platzer C., Emmrich F., Volk H.D. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. Journal of Immunological Methods 1994, 177:23-28.
57. Stüve O., Marra C.M., Bar-Or A., Niino M., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Jerome K.R., Cook L., Grand'Maison F., Hemmer B., Monson N.L., Racke M.K. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Archives of Neurology 2006, 63:1383-1397.
58. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. The Journal of Experimental Medicine 2006, 203:1685-1691.
59. Williams D.P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F., Strom T.B., Murphy J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engineering 1987, 1(6):493-498.
60. Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. Journal of Biological Chemistry 1990, 265:11885-11889.
61. Williams D.P., Wen Z., Watson R.S., Boyd J., Strom T.B., Murphy J.R. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. Journal of Biological Chemistry 1990, 265:20673-20677.
62. Zhang Z., Zhang Z.Y., Schittenhelm J., Wu Y., Meyermann R., Schluesener H.J. Parenchymal accumulation of CD163(+) macrophages/microglia in multiple sclerosis brains. Journal of Neuroimmunology 2011, 237:73-79.